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We read with interest the study by Angiolillo et al. (1) demon-
strating that patients with type 2 diabetes have increased platelet
aggregation on dual aspirin–clopidogrel therapy and that patients
with insulin-treated diabetes mellitus (ITDM) have greater aden-
osine diphosphate (ADP)-induced platelet aggregation compared
with patients with non–insulin-treated diabetes mellitus (NITDM)
(1). This is an important observation as 42% of 15,603 randomized
patients (in the CHARISMA [Clopidogrel for High Athero-
thrombotic Risk and Ischemic Stabilization, Management, and
Avoidance] trial) had diabetes (17% treated with insulin), with no
significant better cardiovascular protection of the clopidogrel plus
aspirin combination versus aspirin alone (2). However, Angiolillo
et al.’s (1) finding and interpretation might be considered by
cardiologists as a counterproductive effect of insulin therapy and
represent an erroneous argument for not switching to insulin those
numerous type 2 diabetic patients with poor glucose control while
on oral treatment.
Type 2 diabetes is a progressive disease. Even if it is true that
patients with ITDM are at a more advanced stage of their
metabolic disorder, the need to switch to insulin reflects profound
insulin secretory defect rather than more severe insulin resistance
(3,4), as erroneously stated by Angiolillo et al. (1). That the higher
proportion of women among ITDM subjects may be considered as
an argument supporting the insulin-resistance hypothesis should
also be challenged, as greater insulin resistance in women than in
men is not a classical finding if appropriately measured (5).
Besides glucose-lowering therapy, the most important clinically
relevant difference between the 2 groups was the 1% difference in
hemoglobin A1c (HbA1c) level (7.9% in ITDM patients vs. 6.9%
in those with NITDM, p  0.001), that is, the same difference as
that reported in the intensive group versus the conventional group
in the United Kingdom Prospective Diabetes Study (6). Angiolillo
et al. (1) suggested that this 1% difference could not explain the
difference in platelet reactivity as HbA1c levels were not correlated
with any of the platelet-function assays performed. This finding is in
contrast to other observations showing a significant influence of
glucose levels on platelet reactivity and effect of antiplatelet agents (7).
According to Angiolillo et al. (1), the study was conducted in a tightly
controlled diabetic population, which led to a limited variability in
HbA1c levels; however, the reported 6% coefficient of variation of
HbA1c levels looks astonishingly low with regard to the mean 
SD data of the 2 subgroups (7.9  1.5% vs. 6.9  1.0%).
A key message from the study by Angiolillo et al. (1) is that
aggressive and/or tailored antithrombotic regimens for high-risk
patients such as diabetic patients may be warranted. However,
emphasizing in the “therapeutic implications” section that “treat-
ment with insulin is typically considered a surrogate of increased
atherothrombotic risk” may be misleading. Although this remains
a controversial issue, numerous data do not support this statement
(8). As diabetologists, the key objective is to obtain adequate
metabolic control (HbA1c 7% and ideally 6.0%), in combina-
tion with aggressive management of all other cardiovascular risk
factors, including effective antiplatelet therapy (9). In numerous
patients, insulin therapy is a necessary and often irreplaceable
partner to tackle hyperglycemia and reach HbA1c targets. Please do
not throw the baby out with the bathwater!
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Reply
We appreciate the comments raised by Drs. Scheen and Legrand.
In their letter, they reveal a status of “apprehension” toward the
potential impact of our study (1) on how clinicians may approach
glucose-control management, in particular, avoiding switching to
insulin in patients not well controlled on oral glucose-lowering
medication. Recognizing the importance of the concerns raised
regarding the potential unintended effects of our investigation (1)
this was neither the intent nor the correct interpretation of our
findings.
628 Correspondence JACC Vol. 49, No. 5, 2007
February 6, 2007:627–9
